

Remarks

Claims 1-76 are pending in the application. The Group II claims have been elected without traverse with the reservation that the Group VI and VII claims may be rejoined in accordance with the provisions of MPEP §821.04. Applicant would like to point out an error in the Group II grouping of claims. Claim 57 should have been included in the Group II claims since it further defines the R^{2a} and R^{2b} substituents and is directly dependent from Claim 56.

Claim 1 has been amended to correspond to the restriction requirement by incorporating the limitations of Claims 5, 12, and 34 into Claim 1 (i.e., A is N, B is C and X is $-CR^{2a}R^{2b}$). Consequently, Claims 5, 12, and 34 have been cancelled. Similarly, Claims 47, 50, 53, 56 have been incorporated into Claim 45 in response to the restriction requirement.

Claims 6-11, 18-30, 32, 35, 39-44, 48, 49, 54, 55, and 59-61 have been cancelled as being directed to non-elected subject matter. Claims 62-76 currently stand withdrawn by the Examiner and subject to rejoinder.

Claims 13, 17, 36, 51, 57, and 58 have been amended to provide proper dependency of claims.

Support for new Claim 77 may be found in Example 2, Example No. 2A-11 in Table 2, of the specification on page 64

Respectfully Submitted:

Date:

June 16, 2005

Arlene K. Musser

Arlene K. Musser
Attorney for Applicants
Registration No. 37,895

Pfizer Inc.
Patent Department, MS: 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871